original articleslung cancerA phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
lung cancer
Under an Elsevier user license
open archive
Keywords
angiokinase inhibitor
BIBF 1120
non-small cell lung cancer
pharmacokinetics
phase II
Cited by (0)
- †
Both authors contributed equally.
Copyright © 2011 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.